XML 36 R26.htm IDEA: XBRL DOCUMENT
v3.23.3

Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Notes Tables |
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] |
|  | September 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
Cash and cash equivalents |  | $ | 3,472 |  |  | $ | 5,362 |
Restricted cash included in other assets |  |  | 476 |  |  |  | 484 |
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows |  | $ | 3,948 |  |  | $ | 5,846 |
Schedules of Concentration of Risk, by Product [Table Text Block] |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Avenova Spray |  | $ | 2,064 |  |  | $ | 1,939 |  |  | $ | 5,759 |  |  | $ | 5,778 |
DERMAdoctor |  |  | 784 |  |  |  | 1,319 |  |  |  | 2,645 |  |  |  | 3,115 |
NeutroPhase |  |  | — |  |  |  | — |  |  |  | 1,043 |  |  |  | 657 |
Other products |  |  | 407 |  |  |  | 558 |  |  |  | 1,524 |  |  |  | 1,193 |
Total product revenue, net |  |  | 3,255 |  |  |  | 3,816 |  |  |  | 10,971 |  |  |  | 10,743 |
Other revenue, net |  |  | 10 |  |  |  | 10 |  |  |  | 28 |  |  |  | 18 |
Total sales, net |  | $ | 3,265 |  |  | $ | 3,826 |  |  | $ | 10,999 |  |  | $ | 10,761 |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] |
|  | September 30, |  |  | December 31, |
Major distribution partner |  | 2023 |  |  | 2022 |
Major U.S. Retailer A |  |  | 26 | % |  |  | * | %
Avenova Spray Pharmacy Distributor A |  |  | 20 | % |  |  | 11 | %
Major International Retailer A |  |  | 10 | % |  |  | * | %
Avenova Spray Pharmacy Distributor B |  |  | * | % |  |  | 30 | %
Major U.S. Retailer B |  |  | * | % |  |  | 15 | %
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
Numerator |  | 2023 |  |  | 2022* |  |  | 2023 |  |  | 2022* |
Net loss |  | $ | (1,757 | ) |  | $ | (136 | ) |  | $ | (5,532 | ) |  | $ | (2,402 | )
Less: Increase in accumulated deficit due to Series B Preferred Stock conversion price |  |  | — |  |  |  | (5,657 | ) |  |  | (1,802 | ) |  |  | (5,657 | )
Less: Increase in accumulated deficit due to Series C Preferred Stock conversion price |  |  | — |  |  |  | — |  |  |  | (194 | ) |  |  | — |
Net loss attributable to common stockholders (basic and diluted) |  | $ | (1,757 | ) |  | $ | (5,793 | ) |  | $ | (7,528 | ) |  | $ | (8,059 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares of common stock outstanding (basic and diluted) |  |  | 4,692 |  |  |  | 1,604 |  |  |  | 3,311 |  |  |  | 1,514 |
Net loss per share (basic and diluted) |  | $ | (0.37 | ) |  | $ | (3.61 | ) |  | $ | (2.27 | ) |  | $ | (5.32 | )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
|  | As of September 30, |
|  | 2023 |  |  | 2022 |
Series B Preferred Stock |  |  | 4,736 |  |  |  | 1,845 |
Series C Preferred Stock |  |  | 845 |  |  |  | — |
Stock options |  |  | 148 |  |  |  | 136 |
Stock warrants |  |  | 7,382 |  |  |  | 65 |
|  |  | 13,111 |  |  |  | 2,046 |

X
- Definition Tabular disclosure of the components of cash, cash equivalents, restricted cash and restricted cash equivalents. + References No definition available. + Details
Name: | nby_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock
Namespace Prefix: | nby_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the concentration of risk by product type. + References No definition available. + Details
Name: | nby_SchedulesOfConcentrationOfRiskByProductTableTextBlock
Namespace Prefix: | nby_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration